January 5, 2017 / 11:09 AM / 7 months ago

BRIEF-Cesca announces FDA approval of IDE supplement for Phase III clinical trial

Jan 5 (Reuters) - Cesca Therapeutics Inc :

* Cesca announces FDA approval of IDE supplement for Phase III clinical trial

* FDA recognized need to increase available patient population in order to properly power clinical trial

* Cesca therapeutics - compared to initial study design, sample size was increased from 224 to 362 patients

* Believe that reduced superiority margin is both achievable and clinically relevant Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below